PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase ( PI3K ) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF). In Vitro PI3K/mTOR Inhibitor-13 sodium (Compound A) (0-2 µM; 48 h) inhibits the proliferation of HFL1 cells with dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: HFL1 cells. Concentration: 0, 0.03125, 0.0125, 0.025, 0.05, 0.0625, 0.1, 0.125, 0.2, 0.25, 0.4, 0.5, 1 and 2 µM. Incubation Time: 48 h. Result: Showed inhibitory for HFL1 cells. Western Blot AnalysisCell Line: HFL1 cells. Concentration: 200 nM. Incubation Time: 48 h. Result: Increased the expression of α-SMA/Tubulin. In Vivo Pharmacokinetic (PK) parameters of PI3K/mTOR Inhibitor-13 sodiumSpecies Administration manner Dose (mg/kg) T 1/2 (h) AUC last (ng•h/mL) Cl/F (L/h/kg) V ss (L/kg) F (%) Rat Intravenous injection 2 2.77 7069 0.29 0.85 94.75 Mice Intravenous injection 1 5.45 57059 0.02 0.13 79.3 Dog Intravenous injection 1 0.67 3672 0.27 0.23 108.5 Monkey Intravenous injection 1 9.70 5978 0.16 0.92 59.8 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid